🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

CORALreef Trials Evaluating Enlicitide - an oral PCSK9 inhibitor

RARE OPPORTUNITY for Lipidaholics - I am often asked how one can view "Dr Lipid" slides! Starting tomorrow evening June 10 and in the subsequent two weeks are 3 free lectures which are part of an exclusive speaker series hosted by Functional Medicine University that are different

📢 We’re proud to be part of a major new joint publication. This paper unites leaders from cardiology and nephrology to drive better use of RAAS inhibitors in clinical care. KIReports Int Society of Nephrology KDIGO RPA-Nephrology AJPC ESC Heart Failure Journal sciencedirect.com/science/articl…

BIG NEWS in the obicetrapib story - fiercebiotech.com/biotech/newams… Patients had significant reductions in the biomarker p-tau217 compared to their counterparts on placebo. The result was statistically significant in the full Alzheimer’s population and in the 367 ApoE4 carriers. Other

We’re pleased to share positive topline results from our Alzheimer's Disease biomarker analyses in the Phase 3 BROADWAY trial. Full results will be presented on July 30th at #AAIC2025. Learn more about the study: bit.ly/3SIOz0t

Some Prep for tomorrows lecture - Lot of info in the graphics. Why is apoB reported as a mass metric and LDL-P as a molar metric? Lipids and Lipoproteins are most often measured and reported as mass (mg) or moles (mol) per unit volume - What is the difference? Register for

I would encourage anyone with a desire to understand the complex topic of preventing heart disease to listen to this masterclass presenter. Dr. Dayspring's pictorial presentations are legendary!

Even though we have known for almost two decades that LDL size is irrelevant once you know total LDL-P or apoB, it is amazing how so many people think size matters and they have to change it. I have been preaching this for so long

For those who would like to see and hear my recent lecture to the Functional Medical University-it is one hour forty minutes long and be prepared to learn a lot and please enjoy:  functionalmedicineuniversity.com/Dayspring-Lipi… National Lipid Association European Atherosclerosis Society ASPC European Society of Cardiology International Atherosclerosis Society (IAS)

After you listen to my lecture be sure to listen to this one with preventive neurologist par excellence Dr Kellyann Niotis https: theinterviewwithleslie.com National Lipid Association European Atherosclerosis Society ASPC European Society of Cardiology Family Heart Foundation European Society of Cardiology

I certainly have to agree with my colleague and friend Pablo that this is an amazing document - Roughly 1.4 billion individuals worldwide are exposed to elevated Lp(a) and the vast majority of them do not know that they are living with this condition and an increased ASCVD risk -

Reminder -- My second lecture for Functional Medicine University is June 17 (tomorrow) - Register for this informative free 1.5-hour lecture on Lipoprotein(a) with my one-of-a-kind graphics at htts://register.gotowebinar.com/register/1416372629896094814 National Lipid Association

This graph should be shown to every first-year medical student after they are taught what apoB is. That also goes for every IM or FP resident or cardiac fellow, and finally the majority of practicing physicians - many of whom, sadly, do not know what apoB is

Repost with correct link: Reminder -- My second lecture for Functional Medicine University is June 17 (tomorrow) - Register for this informative free 1.5-hour lecture on Lipoprotein(a) with my one-of-a-kind graphics at register.gotowebinar.com/register/14163… National Lipid Association International Atherosclerosis Society (IAS)

For those who missed it last night - Here is my Lecture (audio and animated slides) on Lp(a) to the Functional Medicine University - We had > 500 viewers functionalmedicineuniversity.com/LipoproteinLit… National Lipid Association International Atherosclerosis Society (IAS) ASPC European Society of Cardiology International Atherosclerosis Society (IAS) Family Heart Foundation FH Europe Foundation

For those inquisitive about obicetrapib, the up-and-coming CETP inhibitor, watch Archna Bajaj detail the findings of a kinetic lipoprotein study which provides insight on how the med significantly reduces apoB. Like all of the existing apoB-lowering meds, obi upregulates LDL

Weight-Loss Drugs Should Be First Step to Prevent Heart Disease, Top Cardiology Group Says msn.com/en-us/health/o…

Buckle your seatbelts. It was so much fun having my pal Dan Sofer and I telling Simon if he was going to be around much longer. 😂 . National Lipid Association European Atherosclerosis Society ASPC European Society of Cardiology International Atherosclerosis Society (IAS)